Dr Lal Pathlabs has allotted 4,000 equity shares under ESOP on 18 February 2025. With this allotment, the paid up equity share capital has increased to Rs 83,59,17,350/- divided into 8,35,91,735 equity shares of Rs 10/-each. Powered by Capital Market - Live News

Net profit of Dr Lal Pathlabs rose 18.94% to Rs 96.70 crore in the quarter ended December 2024 as against Rs 81.30 crore during the previous quarter ended December 2023. Sales rose 10.73% to Rs 596.70 crore in the quarter ended December 2024 as against Rs 538.90 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales596.70538.90 11 OPM %25.8126.09 - PBDT173.80151.90 14 PBT138.30115.90 19 NP96.7081.30 19 Powered by Capital Market - Live News

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 30 January 2025, inter alia, have recommended the Third Interim dividend of Rs 6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 30 January 2025.Powered by Capital Market - Live News

Dr Lal Pathlabs has allotted 5,483 equity shares under ESOP on 18 December 2024. Pursuant to the above allotment, the Paid-up Equity Share Capital of the Company increased to Rs 83,58,77,350/- divided into 8,35,87,735 equity shares of Rs 10/-each. Powered by Capital Market - Live News